{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:23:45Z","timestamp":1792844625532,"version":"4.5.0"},"reference-count":57,"publisher":"IMR Press","issue":"8","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270443"],"award-info":[{"award-number":["82270443"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82170066"],"award-info":[{"award-number":["82170066"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81670275"],"award-info":[{"award-number":["81670275"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81670443"],"award-info":[{"award-number":["81670443"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2022-NHLHCRF-ZSYX-01"],"award-info":[{"award-number":["2022-NHLHCRF-ZSYX-01"]}]},{"name":"International S&T cooperation program","award":["2013DFA31900"],"award-info":[{"award-number":["2013DFA31900"]}]},{"name":"Major New Drug Creation Special Project, Ministry of Science and Technology of the People\u2019s Republic of China","award":["2020ZX09201-012"],"award-info":[{"award-number":["2020ZX09201-012"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Background: Proprotein convertase subtilisin\/kexin type 9 (PCSK9), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), cholesteryl ester transfer protein (CETP) and apolipoprotein C3 (APOC3) are pivotal regulators of lipid metabolism, with licensed drugs targeting these genes. The use of lipid-lowering therapy via the inhibition of these genes has demonstrated a reduction in the risk of cardiovascular disease. However, concerns persist regarding their potential long-term impact on aortic diseases and calcific aortic valve disease (CAVS). This study aims to investigate causal relationships between genetic variants resembling these genes and aortic disease, as well as calcific aortic valve disease using Mendelian randomization (MR). Methods: We conducted drug-target Mendelian randomization employing summary-level statistics of low-density lipoprotein cholesterol (LDL-C) to proxy the loss-of-function of PCSK9, HMGCR, CETP and APOC3. Subsequently, we investigated the association between drug-target genetic variants and calcific aortic valve stenosis and aortic diseases, including thoracic aortic aneurysm (TAA), abdominal aortic aneurysm (AAA), and aortic dissection (AD). Results: The genetically constructed variants mimicking lower LDL-C levels were associated with a decreased risk of coronary artery disease, validating their reliability. Notably, HMGCR inhibition exhibited a robust protective effect against TAA (odds ratio (OR): 0.556, 95% CI: 0.372\u20130.831, p = 0.004), AAA (OR: 0.202, 95% CI: 0.107\u20130.315, p = 4.84 \u00d7 10-15), and AD (OR: 0.217, 95% CI: 0.098\u20130.480, p = 0.0002). Similarly, PCSK9, CETP and APOC3 inhibition proxies reduced the risk of AAA (OR: 0.595, 95% CI: 0.485\u20130.730, p = 6.75 \u00d7 10-7, OR: 0.127, 95% CI: 0.066\u20130.243, p = 4.42 \u00d7 10-10, and OR: 0.387, 95% CI: 0.182\u20130.824, p = 0.014, respectively) while showing a neutral impact on TAA and AD. Inhibition of HMGCR, PCSK9, and APOC3 showed promising potential in preventing CAVS with odds ratios of 0.554 (OR: 0.554, 95% CI: 0.433\u20130.707, p = 2.27 \u00d7 10-6), 0.717 (95% CI: 0.635\u20130.810, p = 9.28 \u00d7 10-8), and 0.540 (95% CI: 0.351\u20130.829, p = 0.005), respectively. However, CETP inhibition did not demonstrate any significant benefits in preventing CAVS (95% CI: 0.704\u20131.544, p = 0.836). The consistency of these findings across various Mendelian randomization methods, accounting for different assumptions concerning genetic pleiotropy, enhances the causal inference. Conclusions: Our MR analysis reveals that genetic variants resembling statin administration are associated with a reduced risk of AAA, TAA, AD and CAVS. HMGCR, PCSK9 and APOC3 inhibitors but not CETP inhibitors have positive benefits of reduced CAVS. Notably, PCSK9, CETP and APOC3 inhibitors exhibit a protective impact, primarily against AAA, with no discernible benefits extending to TAA or AD.<\/jats:p>","DOI":"10.31083\/j.rcm2508292","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T08:13:01Z","timestamp":1724919181000},"source":"Crossref","is-referenced-by-count":5,"title":["Causal Relationships between Lipid-Lowering Drug Target and Aortic Disease and Calcific Aortic Valve Stenosis: A Two-Sample Mendelian Randomization"],"prefix":"10.31083","volume":"25","author":[{"given":"Liang","family":"Yang","sequence":"first","affiliation":[{"name":"China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, 100029 Beijing, China"},{"name":"Department of Cardiovascular Surgery, China-Japan Friendship Hospital, 100029 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyuan","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, China-Japan Friendship Hospital, 100029 Beijing, China"},{"name":"Peking University China-Japan Friendship School of Clinical Medicine, 100029 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Gao","sequence":"first","affiliation":[{"name":"China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, 100029 Beijing, China"},{"name":"Department of Cardiovascular Surgery, China-Japan Friendship Hospital, 100029 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, China-Japan Friendship Hospital, 100029 Beijing, China"},{"name":"Peking University China-Japan Friendship School of Clinical Medicine, 100029 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingkai","family":"Zhang","sequence":"first","affiliation":[{"name":"China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, 100029 Beijing, China"},{"name":"Department of Cardiovascular Surgery, China-Japan Friendship Hospital, 100029 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohua","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, China-Japan Friendship Hospital, 100029 Beijing, China"},{"name":"Peking University China-Japan Friendship School of Clinical Medicine, 100029 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Ye","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, China-Japan Friendship Hospital, 100029 Beijing, China"},{"name":"Peking University China-Japan Friendship School of Clinical Medicine, 100029 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyan","family":"Wen","sequence":"first","affiliation":[{"name":"Peking University China-Japan Friendship School of Clinical Medicine, 100029 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"first","affiliation":[{"name":"China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Sciences & Peking Union Medical College, 100029 Beijing, China"},{"name":"Department of Cardiovascular Surgery, China-Japan Friendship Hospital, 100029 Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Bossone E, Eagle KA. Epidemiology and management of aortic disease: aortic aneurysms and acute aortic syndromes. Nature Reviews. Cardiology. 2021; 18: 331\u2013348.","DOI":"10.1038\/s41569-020-00472-6"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Song P, He Y, Adeloye D, Zhu Y, Ye X, Yi Q, et al. The Global and Regional Prevalence of Abdominal Aortic Aneurysms: A Systematic Review and Modeling Analysis. Annals of Surgery. 2023; 277: 912\u2013919.","DOI":"10.1097\/SLA.0000000000005716"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Sampson UKA, Norman PE, Fowkes FGR, Aboyans V, Yanna Song, Harrell FE, Jr, et al. Global and regional burden of aortic dissection and aneurysms: mortality trends in 21 world regions, 1990 to 2010. Global Heart. 2014; 9: 171\u2013180.e10.","DOI":"10.1016\/j.gheart.2013.12.010"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. Journal of the American College of Cardiology. 2020; 76: 2982\u20133021.","DOI":"10.1016\/j.jacc.2020.11.010"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Pinard A, Jones GT, Milewicz DM. Genetics of Thoracic and Abdominal Aortic Diseases. Circulation Research. 2019; 124: 588\u2013606.","DOI":"10.1161\/CIRCRESAHA.118.312436"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Nienaber CA, Clough RE, Sakalihasan N, Suzuki T, Gibbs R, Mussa F, et al. Aortic dissection. Nature Reviews. Disease Primers. 2016; 2: 16071.","DOI":"10.1038\/nrdp.2016.53"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Isselbacher EM, Preventza O, Hamilton Black J, 3rd, Augoustides JG, Beck AW, Bolen MA, et al. 2022 ACC\/AHA Guideline for the Diagnosis and Management of Aortic Disease: A Report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 146: e334\u2013e482.","DOI":"10.1161\/CIR.0000000000001097"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Angeloni E, Vitaterna A, Pirelli M, Refice S. Effects of statin therapy on ascending aorta aneurysms growth: A propensity-matched analysis. International Journal of Cardiology. 2015; 191: 52\u201355.","DOI":"10.1016\/j.ijcard.2015.05.001"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Masaki N, Kumagai K, Sasaki K, Matsuo S, Motoyoshi N, Adachi O, et al. Suppressive effect of pitavastatin on aortic arch dilatation in acute stanford type B aortic dissection: analysis of STANP trial. General Thoracic and Cardiovascular Surgery. 2018; 66: 334\u2013343.","DOI":"10.1007\/s11748-018-0916-z"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Takagi H, Goto SN, Matsui M, Manabe H, Umemoto T. A further meta-analysis of population-based screening for abdominal aortic aneurysm. Journal of Vascular Surgery. 2010; 52: 1103\u20131108.","DOI":"10.1016\/j.jvs.2010.02.283"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Takagi H, Manabe H, Umemoto T. A meta-analysis of association between serum lipoproteins and abdominal aortic aneurysm. The American Journal of Cardiology. 2010; 106: 753\u2013754.","DOI":"10.1016\/j.amjcard.2010.06.021"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Salata K, Syed M, Hussain MA, de Mestral C, Greco E, Mamdani M, et al. Statins Reduce Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Mortality: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2018; 7: e008657.","DOI":"10.1161\/JAHA.118.008657"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Yoshimura K, Morikage N, Nishino-Fujimoto S, Furutani A, Shirasawa B, Hamano K. Current Status and Perspectives on Pharmacologic Therapy for Abdominal Aortic Aneurysm. Current Drug Targets. 2018; 19: 1265\u20131275.","DOI":"10.2174\/1389450119666171227223331"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Hosseini A, Sahranavard T, Reiner \u017d, Jamialahmadi T, Dhaheri YA, Eid AH, et al. Effect of statins on abdominal aortic aneurysm. European Journal of Pharmaceutical Sciences: Official Journal of the European Federation for Pharmaceutical Sciences. 2022; 178: 106284.","DOI":"10.1016\/j.ejps.2022.106284"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Stein LH, Berger J, Tranquilli M, Elefteraides JA. Effect of statin drugs on thoracic aortic aneurysms. The American Journal of Cardiology. 2013; 112: 1240\u20131245.","DOI":"10.1016\/j.amjcard.2013.05.081"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Klein KM, Jovin IS. Statins for Patients Undergoing Thoracic Aortic Aneurysm Repair Surgery: What to Do? Aorta (Stamford, Conn.). 2021; 9: 169\u2013170.","DOI":"10.1055\/s-0041-1736589"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Pena RCF, Hofmann Bowman MA, Ahmad M, Pham J, Kline-Rogers E, Case MJ, et al. An assessment of the current medical management of thoracic aortic disease: A patient-centered scoping literature review. Seminars in Vascular Surgery. 2022; 35: 16\u201334.","DOI":"10.1053\/j.semvascsurg.2022.02.007"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Rifai MA, Ballantyne CM. PCSK9-targeted therapies: present and future approaches. Nature Reviews. Cardiology. 2021; 18: 805\u2013806.","DOI":"10.1038\/s41569-021-00634-0"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Rosenson RS, Hegele RA, Fazio S, Cannon CP. The Evolving Future of PCSK9 Inhibitors. Journal of the American College of Cardiology. 2018; 72: 314\u2013329.","DOI":"10.1016\/j.jacc.2018.04.054"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Schmidt AF, Hunt NB, Gordillo-Mara\u00f1\u00f3n M, Charoen P, Drenos F, Kivimaki M, et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nature Communications. 2021; 12: 5640.","DOI":"10.1038\/s41467-021-25703-3"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Tall AR, Thomas DG, Gonzalez-Cabodevilla AG, Goldberg IJ. Addressing dyslipidemic risk beyond LDL-cholesterol. The Journal of Clinical Investigation. 2022; 132: e148559.","DOI":"10.1172\/JCI148559"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Goody PR, Hosen MR, Christmann D, Niepmann ST, Zietzer A, Adam M, et al. Aortic Valve Stenosis: From Basic Mechanisms to Novel Therapeutic Targets. Arteriosclerosis, Thrombosis, and Vascular Biology. 2020; 40: 885\u2013900.","DOI":"10.1161\/ATVBAHA.119.313067"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"de Oliveira S\u00e1 MPB, Cavalcanti LRP, Perazzo \u00c1M, Gomes RAF, Clavel MA, Pibarot P, et al. Calcific Aortic Valve Stenosis and Atherosclerotic Calcification. Current Atherosclerosis Reports. 2020; 22: 2.","DOI":"10.1007\/s11883-020-0821-7"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Nazarzadeh M, Pinho-Gomes AC, Bidel Z, Dehghan A, Canoy D, Hassaine A, et al. Plasma lipids and risk of aortic valve stenosis: a Mendelian randomization study. European Heart Journal. 2020; 41: 3913\u20133920.","DOI":"10.1093\/eurheartj\/ehaa070"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, et al. Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease. JAMA. 2019; 321: 364\u2013373.","DOI":"10.1001\/jama.2018.20045"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Nicholls SJ, Lincoff AM, Garcia M, Bash D, Ballantyne CM, Barter PJ, et al. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial. JAMA. 2020; 324: 2268\u20132280.","DOI":"10.1001\/jama.2020.22258"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, et al. Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes. The New England Journal of Medicine. 2016; 375: 2144\u20132153.","DOI":"10.1056\/NEJMoa1604304"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. Nature Genetics. 2013; 45: 1274\u20131283.","DOI":"10.1038\/ng.2797"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. Nature Genetics. 2015; 47: 1121\u20131130.","DOI":"10.1038\/ng.3396"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Kurki MI, Karjalainen J, Palta P, Sipil\u00e4 TP, Kristiansson K, Donner KM, et al. FinnGen provides genetic insights from a well-phenotyped isolated population. Nature. 2023; 613: 508\u2013518.","DOI":"10.1038\/s41586-022-05473-8"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Rosoff DB, Bell AS, Jung J, Wagner J, Mavromatis LA, Lohoff FW. Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function. Journal of the American College of Cardiology. 2022; 80: 653\u2013662.","DOI":"10.1016\/j.jacc.2022.05.041"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Lawlor DA, Harbord RM, Sterne JAC, Timpson N, Davey Smith G. Mendelian randomization: using genes as instruments for making causal inferences in epidemiology. Statistics in Medicine. 2008; 27: 1133\u20131163.","DOI":"10.1002\/sim.3034"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genetic Epidemiology. 2016; 40: 304\u2013314.","DOI":"10.1002\/gepi.21965"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. International Journal of Epidemiology. 2015; 44: 512\u2013525.","DOI":"10.1093\/ije\/dyv080"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nature Genetics. 2018; 50: 693\u2013698.","DOI":"10.1038\/s41588-018-0099-7"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Cai J, Wei Z, Chen M, He L, Wang H, Li M, et al. Socioeconomic status, individual behaviors and risk for mental disorders: A Mendelian randomization study. European Psychiatry: the Journal of the Association of European Psychiatrists. 2022; 65: e28.","DOI":"10.1192\/j.eurpsy.2022.18"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Yarmolinsky J, Bull CJ, Vincent EE, Robinson J, Walther A, Smith GD, et al. Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer. JAMA. 2020; 323: 646\u2013655.","DOI":"10.1001\/jama.2020.0150"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Benn M, Nordestgaard BG, Frikke-Schmidt R, Tybj\u00e6rg-Hansen A. Low LDL cholesterol, PCSK9 and HMGCR genetic variation, and risk of Alzheimer\u2019s disease and Parkinson\u2019s disease: Mendelian randomisation study. BMJ (Clinical Research Ed.). 2017; 357: j1648.","DOI":"10.1136\/bmj.j1648"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. European Journal of Epidemiology. 2017; 32: 377\u2013389.","DOI":"10.1007\/s10654-017-0255-x"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Zhang L, Issa Bhaloo S, Chen T, Zhou B, Xu Q. Role of Resident Stem Cells in Vessel Formation and Arteriosclerosis. Circulation Research. 2018; 122: 1608\u20131624.","DOI":"10.1161\/CIRCRESAHA.118.313058"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Sakalihasan N, Michel JB, Katsargyris A, Kuivaniemi H, Defraigne JO, Nchimi A, et al. Abdominal aortic aneurysms. Nature Reviews. Disease Primers. 2018; 4: 34.","DOI":"10.1038\/s41572-018-0030-7"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003; 23: 769\u2013775.","DOI":"10.1161\/01.ATV.0000068646.76823.AE"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Yoshida O, Kondo T, Kureishi-Bando Y, Sugiura T, Maeda K, Okumura K, et al. Pitavastatin, an HMG-CoA reductase inhibitor, ameliorates endothelial function in chronic smokers. Circulation Journal: Official Journal of the Japanese Circulation Society. 2010; 74: 195\u2013202.","DOI":"10.1253\/circj.CJ-09-0345"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Kassan M, Montero MJ, Sevilla MA. In vitro antioxidant activity of pravastatin provides vascular protection. European Journal of Pharmacology. 2010; 630: 107\u2013111.","DOI":"10.1016\/j.ejphar.2009.12.037"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. The New England Journal of Medicine. 2017; 376: 1713\u20131722.","DOI":"10.1056\/NEJMoa1615664"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Roychowdhury T, Klarin D, Levin MG, Spin JM, Rhee YH, Deng A, et al. Genome-wide association meta-analysis identifies risk loci for abdominal aortic aneurysm and highlights PCSK9 as a therapeutic target. Nature Genetics. 2023; 55: 1831\u20131842.","DOI":"10.1038\/s41588-023-01510-y"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, Rigby SP, Kling D, Curcio DL, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nature Medicine. 2022; 28: 1672\u20131678.","DOI":"10.1038\/s41591-022-01936-7"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Ginsberg HN, Goldberg IJ. Broadening the Scope of Dyslipidemia Therapy by Targeting APOC3 (Apolipoprotein C3) and ANGPTL3 (Angiopoietin-Like Protein 3). Arteriosclerosis, Thrombosis, and Vascular Biology. 2023; 43: 388\u2013398.","DOI":"10.1161\/ATVBAHA.122.317966"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Yan AT, Koh M, Chan KK, Guo H, Alter DA, Austin PC, et al. Association Between Cardiovascular Risk Factors and Aortic Stenosis: The CANHEART Aortic Stenosis Study. Journal of the American College of Cardiology. 2017; 69: 1523\u20131532.","DOI":"10.1016\/j.jacc.2017.01.025"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. The New England Journal of Medicine. 2005; 352: 2389\u20132397.","DOI":"10.1056\/NEJMoa043876"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Rosseb\u00f8 AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. The New England Journal of Medicine. 2008; 359: 1343\u20131356.","DOI":"10.1056\/NEJMoa0804602"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010; 121: 306\u2013314.","DOI":"10.1161\/CIRCULATIONAHA.109.900027"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Nienaber CA, Yuan X. Lipid levels linked to symptomatic aortic valve stenosis: evidence from Mendelian randomization? European Heart Journal. 2020; 41: 3921\u20133924.","DOI":"10.1093\/eurheartj\/ehaa225"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Harrison SC, Holmes MV, Burgess S, Asselbergs FW, Jones GT, Baas AF, et al. Genetic Association of Lipids and Lipid Drug Targets With Abdominal Aortic Aneurysm: A Meta-analysis. JAMA Cardiology. 2018; 3: 26\u201333.","DOI":"10.1001\/jamacardio.2017.4293"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"Ference BA. Interpreting the Clinical Implications of Drug-Target Mendelian Randomization Studies. Journal of the American College of Cardiology. 2022; 80: 663\u2013665.","DOI":"10.1016\/j.jacc.2022.06.007"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"Chen Y, Huang M, Xuan Y, Li K, Xu X, Wang L, et al. Association between Lipid Levels and Risk for Different Types of Aneurysms: A Mendelian Randomization Study. Journal of Personalized Medicine. 2021; 11: 1171.","DOI":"10.3390\/jpm11111171"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"Li R, Zhang C, Du X, Chen S. Genetic Association between the Levels of Plasma Lipids and the Risk of Aortic Aneurysm and Aortic Dissection: A Two-Sample Mendelian Randomization Study. Journal of Clinical Medicine. 2023; 12: 1991.","DOI":"10.3390\/jcm12051991"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/25\/8\/10.31083\/j.rcm2508292","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T19:30:15Z","timestamp":1732735815000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/25\/8\/10.31083\/j.rcm2508292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":57,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024]]}},"alternative-id":["S1530-6550(24)01343-7"],"URL":"https:\/\/doi.org\/10.31083\/j.rcm2508292","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"article-number":"292"}}